March of Dimes, the national leader in maternal and infant health research, today announced Thomas Jansson, MD, PhD, a global leader in the field of placental function, mother-baby nutrient transfer, ...
Phase 3 SELVA study evaluating QTORIN™ rapamycin 3.9% anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic ...
Phase 3 SELVA study evaluating QTORIN rapamycin 3.9% anhydrous gel (QTORIN rapamycin) for microcystic lymphatic malformations (microcystic LMs) remains on track, with topline results anticipated in Ma ...
Oxford Drug Design has announced new in vivo results that further validate its emerging first‑in‑class oncology programme, ...
AI and machine learning are revolutionizing drug discovery, development, and lifecycle management, addressing industry ...
Detailed price information for Palvella Therapeutics Inc (PVLA-Q) from The Globe and Mail including charting and trades.
Menopause, when a woman’s period ceases, is a stark example of the consequences of ovarian aging. It occurs when the ovaries ...
Oxford Drug Design, the Oxford-based AI drug discovery company, has announced an important milestone in the development of ...
WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) is moving toward what could be a defining year, with a late-stage ...
Scientists at Duke-NUS Medical School have uncovered how exercise helps aging muscles regain their ability to repair ...
A newly developed radiopharmaceutical pair can precisely detect and effectively treat gastric and pancreatic tumors, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback